Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Low-Dose Temozolomide in Recurrent Malignant Glioma
NCT00498927Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2007
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of temozolomide in malignant glioma, glioblastoma multiforme (GBM), sponsored by Memorial Sloan Kettering Cancer Center. Started Jun 2007; status: completed.
02
Drugs
temozolomide
03
Conditions
malignant gliomaglioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00498927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00498927.